Navigation Links
Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
Date:5/23/2012

MONMOUTH JUNCTION, N.J., May 23, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2 clinical trial, Treatment with ARIKACE to Realize Greater Efficacy Trial (TARGET-NTM), of ARIKACE® (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease.

There have been very few clinical trials to support current NTM treatment recommendations, and no new drugs have been assessed in randomized trials for NTM lung disease in many years.   Additionally, NTM remains a significantly under-diagnosed disease.  TARGET-NTM represents an opportunity to make significant advancement in the awareness and treatment of this debilitating chronic illness, according to Kenneth N. Olivier, M.D., M.P.H., Principal Investigator of the study and staff pulmonologist in the Laboratory of Clinical Infectious Diseases at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

"Current treatment for NTM lung disease requires lengthy multi-drug regimens that can be poorly tolerated and have limited efficacy, especially in patients with severe disease or in those who have failed prior treatment attempts," said David E. Griffith, M.D., lead author of the American Thoracic Society's and the Infectious Disease Society of America's diagnosis and treatment guidelines for NTM, and Professor of Medicine at the University of Texas Health Science Center at Tyler. "If effective, ARIKACE has the potential to significantly impact the current NTM treatment paradigm."  Dr. Griffith, along with Richard J Wallace, M.D., Professor of Medicine and Microbiology, also at the University of Texas Health Science Center at Tyler, are Co-Principal Investigators for the study.

NTM Increasingly Prevalent

According to a
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Insmed Announces First Quarter 2012 Financial Results
2. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
3. Insmed to Host 2012 First Quarter Earnings Conference Call
4. Insmed to Host Fourth Quarter and 2011 Year-End Earnings Conference Call
5. Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference
6. Insmed Incorporated Provides Regulatory Update on ARIKACE® in Non-Tuberculous Mycobacteria Indication
7. Insmed Incorporated Provides Regulatory Update
8. Insmed to Present at Sixth Annual JMP Securities Healthcare Conference
9. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011
10. Insmeds ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
11. Insmed Announces First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  Array BioPharma Inc. (NASDAQ: ... quarter and full year of its fiscal year ... Chief Executive Officer of Array, noted, "Binimetinib and encorafenib, ... on track for regulatory submissions in 2016. Additional ... and BRAF-mutant colorectal cancer further validate the value ...
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, ... met its primary and secondary endpoints in a phase ... constipation (OIC) in adult patients with chronic non-cancer pain. ... antagonist (PAMORA). This is the third Phase III trial ... endpoints. Study results showed that a 0.2 ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR ... specializing in the development, manufacturing, and marketing of branded ... annual general meeting of shareholders (the "Meeting") will be ... Beijing time. The meeting will be held at No.699-18, ...
... /PRNewswire-iReach/ -- Global Information Inc. is pleased to ... Therapy market: Global Protein Therapeutics Market ... become one of the most effective clinical methods to ... metabolic disorders. While worldwide healthcare spending has decline in the ...
Cached Medicine Technology:Simcere Pharmaceutical Group Provides Notice of Annual General Meeting 2New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015 2
(Date:8/3/2015)... ... August 03, 2015 , ... ... contract research organisations (CROs) for a slew of benefits, allowing them to gain ... operations, boost quality with cost-effective utilisation of resources, get access to innovation and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in Los Angeles ... need. Most people know that general health emergencies, such as broken arms or a ... people know where to turn to during a dental emergency. This is important, because ...
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader ... present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) ... archived replay of the Company’s presentation may be accessed via the investor relations section ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... A July ... Injection of Stem Cells Found to Release Natural Painkiller That Can Last 'For Five ... patients. According to the report, the new study showed that harvesting stem cell-rich bone ...
(Date:8/3/2015)... ... August 03, 2015 , ... Constantin Vasilica, 48 from Romania wanted to ... by diabetes after many years of suffering and using medications with strong side effects. ... to ask for extra time off or wait longer hours in the waiting rooms. ...
Breaking Medicine News(10 mins):Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3
... Introduces New Educational ... Resource at IDSA Annual Meeting, HADDON HEIGHTS, ... a new continuing education,resource as part of their exhibit booth ... America (IDSA), October 4-7, in San Diego,California. Project CDAD: Outbreak ...
... reveal new ways of controlling and treating breast cancer ... today (Monday 1 October 2007). , Dr Robert Clarke ... group have been investigating human breast cancers for the ... tumours and can cause the cancer to recur - ...
... CHICAGO, Oct. 1 Y-ME Illinois will host a ... and,friends. The BIG Night Out - Indulgence for ... 6:30 p.m. to 10:00 p.m. in the Great Hall ... pamper themselves by,partaking in indulgences such as onsite spa ...
... Oct. 1 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,Corp. today ... signed amended,agreements with Smith & Nephew wound ... dressings with SILCRYST(TM) nanocrystalline coatings.,The two companies ... when Smith &,Nephew bought the Acticoat(TM) brand ...
... WINDSOR, Conn., Oct. 1 UTC Power, a,United ... announced it has,acquired Dome- Tech Group, a national ... New York City. Financial terms were not disclosed. ... energy costs,and improve overall efficiency. It facilitates green, ...
... Achieve Optimum Health, SOMERSET, N.J., Oct. 1 ... announced that it has launched a fourth business,segment, ... pharmaceutical,companies and healthcare payors achieve the best possible ... and stay on the right therapy, everyone wins ...
Cached Medicine News:Health News:National Experts Team Up to Help Hospitals Prevent and Control C. difficile Outbreaks 2Health News:Manchester researchers announce new methods of beating breast cancer 2Health News:Y-ME Illinois Hosts the First-Ever 'BIG Night Out' - Indulgence for a Cause 2Health News:NUCRYST and Smith & Nephew Revise Agreements 2Health News:NUCRYST and Smith & Nephew Revise Agreements 3Health News:NUCRYST and Smith & Nephew Revise Agreements 4Health News:NUCRYST and Smith & Nephew Revise Agreements 5Health News:NUCRYST and Smith & Nephew Revise Agreements 6Health News:NUCRYST and Smith & Nephew Revise Agreements 7Health News:UTC Power Acquires Dome-Tech Group 2Health News:inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes 2Health News:inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes 3
This portable resource provides definitions for medical acronyms and abbreviations....
Stedman's Medical Dictionary includes charts and tables and navigation and search tools....
With Skyscape's smARTlink technology, Tabers can cross-index with other clinical and drug prescription products from Skyscape to provide an integrated source of clinical information....
CPTMeister is a coding reference based on the Physicians' Current Procedural Terminology (CPT) codes developed by the American Medical Association. It is an iSilo document composed of more than 2,000...
Medicine Products: